Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bisphosphocins - Lakewood-Amedex

Drug Profile

Research programme: bisphosphocins - Lakewood-Amedex

Alternative Names: Bisphosphocins; Nu 2; Nu 4; Nu 5; Nu 8; NuBiotics - Lakewood-Amedex; Nubiotics research programme - Oligos Etc.

Latest Information Update: 11 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oligos Etc.
  • Developer Lakewood Amedex
  • Class Antibacterials; Nucleotides
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Infections; Urinary tract infections

Most Recent Events

  • 04 Apr 2017 Lakewood-Amedex plans to file an IND application for NU 8 for Urinary tract infections
  • 04 Apr 2017 Antimicrobial data from preclinical studies in Infections released by Lakewood-Amedex
  • 23 Jan 2017 Preclinical trials in Urinary tract infections in USA (IV) before January 207 (Lakewood Amedex pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top